While azithromycin interferes with the bacteria's ability to make proteins, and
ceftriaxone causes the cell wall to fall apart, this new drug acts on a crucial protein involved in bacterial DNA replication.
Madrid, Spain: The antibiotic combination treatment piperacillin - tazobactam was significantly less effective than meropenem when treating potentially fatal bloodstream infections (BSI)
caused by
ceftriaxone - resistant Escherichia coli and Klebsiella pneumoniae and should be avoided when treating these organisms, according to research presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)[1].